Publications – Bernard Fox

Sandra Prior, Simon E. Hufton, Bernard Fox, Thomas Dougall, Peter Rigsby, Adrian Bristow & participants of the study. International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab. mAbs. 2018; 10(1), 129-142.


SJ Thorpe, C Ball, B Fox, KM Thompson, R Thorpe and A Bristow. Anti-Rh D and anti-i activities are inseparable in V\(_{34}\)-encoded monoclonal anti-Rh D: the same framework 1 residues are required for both reactivities. Transfusion 2008; 48, 930-940.

R Stebbings, L Findlay, C Edwards, C Bird, D North, D Eastwood, Y Mistry, P Dilger, E Liefooghe, I Cludts, B Fox, G Tarrant, J Robinson, T Meager, C Dolman, S Thorpe, A Bristow, M Wadhwa, R Thorpe, S Poole. TGN1412 “Cytokine Storm” in the Phase 1 Trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. Journal of Immunology 2007; 179: 3325-3331


SJ Thorpe, BJ Fox, CD Dolman, J Lawrence and R Thorpe. Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity. Vox Sanguinis 2003; 85: 80-84


Fox BJ: Kinetics of Anti-D binding to Rh D+ erythrocytes. Transfusion Medicine 1997; 7 (Suppl. 1): 11